Evaluation of Variable-Dose Treatment with a New U.S. Botulinum Toxin Type A (Dysport) for Correction of Moderate to Severe Glabellar Lines: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Authors:
- Fredric BrandtFBFredric Brandt
- Rod J. RohrichRRRod J. Rohrich
- Rhoda S. NarinsRNRhoda S. Narins
- Gary D. MonheitGMGary D. Monheit
- M Barbara HuberMHM Barbara Huber
- 1 November 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 124 (5) , 1619-1629
Abstract
In April, the U.S. Food and Drug Administration approved a new U.S. formulation of botulinum neurotoxin type A (Dysport; Medicis Aesthetics, Inc., Scottsdale, Ariz.). This formulation has demonstrated inhibition of glabellar lines at a 50-unit dose. Standard clinical practice is to adjust the dose based on muscle mass. Patients stratified by race/ethnicity were randomized to receive a single treatment of Dysport administered in various doses or placebo. Dysport was administered in a total volume of 0.4 to 0.6 ml for women (50, 60, or 70 units) and 0.5 to 0.7 ml for men (60, 70, or 80 units), based on procerus/corrugator muscle mass. Efficacy was assessed by a blinded evaluator and patient self-evaluation on days 14, 30, 60, 90, 120, and 150 after treatment. At day 30, 85 percent and 87 percent of Dysport-treated patients were responders as assessed by blinded evaluator and patient self-evaluation, respectively, compared with 3 percent and 5 percent of placebo-treated patients, respectively (p < 0.001). Median duration of effect was 109 days for Dysport versus 0 days for placebo (blinded evaluator) and 107 days for Dysport versus 0 days for placebo (patient self-evaluation). Response and duration of action were slightly higher in African American patients. The majority of treatment-emergent adverse events were mild or moderate in severity. A single treatment with Dysport, with the dose based on gender and muscle mass, is well tolerated and provides a greater and longer-lasting improvement in glabellar lines compared with placebo.Keywords
This publication has 9 references indexed in Scilit:
- Long-term Safety and Efficacy of a New Botulinum Toxin Type A in Treating Glabellar LinesArchives of Facial Plastic Surgery, 2009
- A Randomized, Double‐Blind, Placebo‐Controlled Study of Botulinum Toxin Type A for the Treatment of Glabellar LinesDermatologic Surgery, 2007
- Repeated Botulinum Toxin A Injections for the Treatment of Lines in the Upper FaceDermatologic Surgery, 2007
- Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized studyJournal of the American Academy of Dermatology, 2006
- Botulinum toxin type AJournal of the American Academy of Dermatology, 2005
- Botulinum toxin A in the treatment of glabellar lines: Scheduling the next injectionAesthetic Surgery Journal, 2005
- A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar linesJournal of the American Academy of Dermatology, 2004
- Reproducibility of a four-point clinical severity score for glabellar frown linesBritish Journal of Dermatology, 2003
- A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJournal of the American Academy of Dermatology, 2002